Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b in ET and PV
NCT06734637Recruiting
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of peginterferon alfa-2b in essential thrombocythemia (ET) and polycythemia vera (PV). Primary endpoint: Hematologic remission rate at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06734637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734637.